Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients treated with tocilizumab therapy

From: CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis

  Baseline (n = 36) Week 12 (n = 36) Week 24 (n = 36) 1 year (n = 36)
Age, median (range) years 54 (33-79)    
% female 77%    
Disease duration, median (range) years 9 (2-33)    
RF positive 36
ACPA positive 28
RF/ACPA positive 28  
  mean ± SEM    
DAS28 score 5.2 ± 0.3 3.3 ± 0.3ψ 2.7 ± 0.2ψ 1.9 ± 0.2ψ
CRP, mg/dl 0.9 ± 0.1 0.14 ± 0.06ψ 0.09 ± 0.03ψ 0.06 ± 0.02ψ
ESR, mm/hour 32.1 ± 3.4 9.8 ± 1.6ψ 7.2 ± 0.9ψ 5.6 ± 0.8ψ
Patient’s VAS 58.3 ± 4.4 48.6 ± 4.8ψ 34.8 ± 5.4ψ 21.5 ± 4.8ψ
IgA-RF U/ml 122.3 ± 33.3 99.9 ± 26.3ψ 63.3 ± 19.8ψ -
IgA total U/ml 265.4 ± 20.8 237.2 ± 19.5ψ 203.1 ± 18.9ψ -
  1. The primary end point of the study was a reduction in the disease activity score in 28 joints (DAS28) at week 12. Except where indicated otherwise, values are the mean ± standard error of the mean (SEM). ψ P <0.05 versus baseline and Mann-Whitney t test was used for statistics. RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS, visual analog scale (100 mm); IgA, immunoglobulin A.